Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma

Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma

Abstract Background Adrenocortical carcinoma (ACC) is a highly malignant urologic cancer and tends to metastasize. Although immune checkpoint inhibitors (ICIs) bring a glimmer of light to conquer ACC, only a fraction of patients have benefit from ICIs treatment. It is well known that tumor mutationa...

Full description

Bibliographic Details
Main Authors: Fangshi Xu, Yibing Guan, Peng Zhang, Li Xue, Yubo Ma, Mei Gao, Tie Chong, Bin-Cheng Ren
Format: Article
Language:English
Published: BMC 2022-05-01
Series:BMC Endocrine Disorders
Subjects:
Tumor mutational burden
Adrenocortical carcinoma
Immune checkpoint inhibitors
Immune microenvironment
Prognosis
Online Access:https://doi.org/10.1186/s12902-022-01017-3

Internet

https://doi.org/10.1186/s12902-022-01017-3

Similar Items